Robbins LLP has kicked off a class action lawsuit for investors who bought shares of Regeneron Pharmaceuticals,Inc. (NASDAQ: REGN) between August 1, 2025,and May 15,2026. Allegations claim the pharma giant misled investors about Phase III Fianlimab-Libtayo Study's effectiveness,a trial for a new advanced melanoma treatment.
The Phase III study, enrolling participants since mid-2022, aimed to test Fianlimab, a human monoclonal antibody, with Libtayo as a first-line therapy. But plaintiffs say Regeneron hyped up the study's potential while hiding key problems. They allege flawed statistical assumptions and no major clinical gains over current treatments.
On April 29,2026,during an earnings call,Regeneron announced changes to the Phase III study,upping patient numbers for analyzing progression-free survival. This news sent the stock tumbling from $731.77 on April 28 to $686.36 on April 29,a 6.2% drop in a single day .
Investor worries grew when on May 15,2026,Regeneron admitted the trial missed its main goal of improving progression-free survival . The stock nosedived again, from $698.25 to $629.68 by May 18, a near 9.8% fall in two days.
Investors who bought Regeneron shares during this time might join the class action. Those wanting to lead the lawsuit can contact Robbins LLP. But joining isn't required for potential recovery; investors can stay as absent class members.
Robbins LLP works on contingency, so shareholders won't pay unless the case wins. The firm boasts a solid record in shareholder rights cases, recovering over $1 billion and securing governance reforms at many Fortune 1000 firms.
Brian J. Robbins,the firm's founding partner, stressed the need for corporate accountability and transparency. He said, "Everything we do is driven by belief that companies should be responsibly governed,fiduciaries held accountable,and shareholders deserve transparency and fairness."
Investors wanting updates on the class action or alerts on corporate misconduct can sign up for Stock Watch,a service by Robbins LLP. Shareholders suspecting they were affected by Regeneron’s actions should reach out for details.
As legal proceedings continue, stakes are high for Regeneron and its investors. The class action's outcome could change investor relations and corporate accountability in the pharma sector...
